Cardiol Therapeutics Inc (CRDL) Stock Analysis
Verdict: WATCH (do not buy)
Clinical-stage binary play: $21M cash vs $24M burn creates a 10-month runway, making clinical data or dilution the next major catalyst.
Investment score: 48/100
Analysis as of
Is Cardiol Therapeutics Inc stock worth reviewing? The TradeMates thesis
Cardiol is a pre-revenue biotech with a ticking clock on its cash reserves. Hold for clinical data, but expect dilution.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 40/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 50/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Cardiol Therapeutics Inc opportunities and risks
What speaks for CRDL
- Orphan Drug Potential
What speaks against CRDL
- Imminent Liquidity Event
Peers and competitors
- XLY.TO
- HITI.V
- TSND.TO
- ACB.TO
- CRDL.TO
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CRDL | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.0% |
| XLY.TO | 7.6x | 1.7x | 5.7x | 47.5% | 20.9% | 12.2% |
| HITI.V | n/a | 0.4x | n/a | 17.5% | -6.6% | 5.7% |
| TSND.TO | n/a | 0.6x | 6.1x | 50.9% | -31.2% | 9.9% |
| ACB.TO | n/a | 0.8x | n/a | 56.6% | -24.1% | -14.6% |
| CRDL.TO | n/a | 0.0x | n/a | 0.0% | 0.0% | -12.0% |
| Peer median | n/a | 0.6x | n/a | 47.5% | -6.6% | 5.7% |
Frequently asked questions about Cardiol Therapeutics Inc (CRDL)
Is CRDL stock a good investment?
The TradeMates model rates Cardiol Therapeutics Inc as WATCH (do not buy) with an investment score of 48/100. Cardiol is a pre-revenue biotech with a ticking clock on its cash reserves. Hold for clinical data, but expect dilution. This is algorithmic model output, not personal investment advice.
Is CRDL stock a buy?
The TradeMates model verdict for CRDL is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.